title: Preparation and in vitro characterization of amifostine biodegradable microcapsules.
abstract: The purpose of this project was to develop sustained release microcapsules of amifostine. The microcapsules were prepared using solvent evaporation technique. The effect of several formulation variables on the characteristics of the microcapsules was studied. The formulation variables studied were drug loading, polymer (polylactide-co-glycolide) (PLGA) concentration, and the amount of gelatin in the initial aqueous phase. The drug loading was studied at three different levels (5, 10, and 25 mg); the PLGA concentration was studied at two levels (500 and 1000 mg); and the amount of gelatin used ranged from 2 to 14 mg. In general, the microcapsules were less than 155 microm in diameter with median size between 50 and 80 microm. While the use of higher amounts of PLGA significantly increased the median size of the microcapsules, using higher amounts of amifostine had no significant effect, irrespective of the amount of PLGA. The use of gelatin, within the range 2-14 mg, did not show any significant effect on the particle size distribution. Scanning electron microscopy (SEM) of the microcapsules revealed that all nine formulations yielded spherical particles. The use of 500 mg PLGA with 10 or 25 mg amifostine yielded microcapsules with porous surfaces. The surface pores, however, were not present in microcapsules prepared using 1000 mg PLGA. The efficiency of encapsulation decreased significantly from 63 to 24% when the amount of amifostine increased from 5 to 25 mg in the formulations using 500 mg PLGA. Similarly, the efficiency of encapsulation decreased from 87 to 23% when the amount of PLGA was doubled to 1000 mg. An increase in the amount of amifostine in the formulation using 500 mg PLGA also resulted in a significant increase in initial drug release (from 20 to 62%) within the first hour. These results were consistent with the porous morphology of these microcapsules. In general, all batches of microcapsules showed 24-96 h sustained drug release.
authors.affiliation: College of Pharmacy, Xavier University of Louisiana, New Orleans, LA 70125-1098, USA.
authors.forename: Sarala
authors.initials: S
authors.lastname: Pamujula
authors.forename: Richard A
authors.initials: RA
authors.lastname: Graves
authors.forename: Vimal
authors.initials: V
authors.lastname: Kishore
authors.forename: Tarun K
authors.initials: TK
authors.lastname: Mandal
mesh_terms: D004999:Amifostine / Q000138:chemical synthesis* / Q000493:pharmacokinetics*; D001711:Biotransformation; D002214:Capsules; D012995:Solubility / Q000187:drug effects
chemical_list: D002214:Capsules; D004999:Amifostine